Invention Publication
- Patent Title: BIOENGINEERED IMMUNOMODULATORY FUSION PROTEIN COMPOSITIONS
-
Application No.: US18549795Application Date: 2022-03-11
-
Publication No.: US20240166720A1Publication Date: 2024-05-23
- Inventor: Ninkka TAMOT , Paul B. HARVILLA , Douglas YAMADA , Manuel Alejandro SEPULVEDA , Rajkumar GANESAN , Sanjaya SINGH
- Applicant: Janssen Biotech, Inc.
- Applicant Address: US PA Horsham
- Assignee: Janssen Biotech, Inc.
- Current Assignee: Janssen Biotech, Inc.
- Current Assignee Address: US PA Horsham
- International Application: PCT/US2022/019926 2022.03.11
- Date entered country: 2023-09-08
- Main IPC: C07K14/705
- IPC: C07K14/705 ; A61K39/00 ; A61K39/39 ; A61P37/04

Abstract:
Provided herein are bioengineered immunomodulatory fusion proteins and uses thereof for modulating immune responses, as well as uses for improving a response of a subject to a vaccine, or uses for treating a disease or disorder, such as cancer or a pathogen infection. Provided herein is a single chain trimeric CD40L Fc fusion protein comprising (a) three CD40 ligand CD40L subunits covalently linked to one another by peptide linkers (CD40L trimer); and (b) an Fc monomer peptide.
Information query